The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.
 
Dirk Schadendorf
Honoraria - 4SC; Amgen; Array BioPharma; Bristol-Myers Squibb; Daiichi Sankyo Japan; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; Nektar; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis
 
Mario Mandalà
Honoraria - Bristol-Myers Squibb/Sanofi; MSD Oncology; Novartis; Pierre Fabre; Sanofi/Aventis
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre
Research Funding - Novartis (Inst)
 
John M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Ankyra Therapeutics; AXIO Research; Becker Pharmaceutical Consulting; Checkmate Pharmaceuticals; DermTech; Fenix Group International; Harbour BioMed; Immunocore; Intellisphere, LLC; Iovance Biotherapeutics; IQVIA; Istari Oncology; Merck; Natera; Novartis; Oncocyte; OncoSec; Pfizer; Replimune; Scopus BioPharma; SR One Capital Management; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst); Schering-Plough (Inst); Takeda (Inst); Verastem (Inst)
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis (Inst)
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Paul D. Nathan
Consulting or Advisory Role - 4SC; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Michael A. Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; NanoString Technologies; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Hiya Banerjee
Employment - Novartis
 
Rohan Shah
Employment - Novartis
 
Mike R. Lau
Employment - Novartis; Novartis (I)
Stock and Other Ownership Interests - Novartis
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; Provectus; QBiotics; Regeneron; Skyline Diagnostics